SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around a potential listing on Bifinance and anticipates a token burn upon reaching 2000 watchers. The community emphasizes its resilience and commitment to organic growth, contrasting $BROKE.X with other meme coins. Active community members are encouraging others to research the project and join their movement towards financial freedom.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending due to high volume and trader activity, with community members pointing to recent price gains and comparing it to other DeFi gainers. Conversations suggest excitement around its features, potential for new all-time highs, and speculation about hitting certain price targets.  Some users are also mentioning the project's backers and the possibility of listings on major exchanges.

TOSHI

TOSHI.X is trending strongly as the community celebrates recent listings on multiple exchanges and anticipates further expansion. Bullish sentiment is fueled by the coin's association with Coinbase and the Base network, with many community members expressing excitement about its potential for significant gains. The conversation highlights a growing belief that Toshi is poised for substantial growth in the meme coin sector.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

PHUM.X is gaining attention as a potential "sleeper gem" within the Solana ecosystem, with community members actively encouraging others to buy in early. The token is generating buzz, with many highlighting its chart strength and anticipating a breakout. Some users are also emphasizing the importance of teamwork and community support for the token's success.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics (CAPR) is trending as investors await news from the FDA regarding the path forward for its DMD treatment, Deramiocel, following a prior rejection. Community discussion revolves around the potential for accelerated approval and the impact of HOPE-3 trial data, with some expressing concerns about FDA transparency and potential short squeezes. The focus remains on the FDA's decision and Deramiocel's potential to address unmet needs in Duchenne muscular dystrophy.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, and the community is actively asking, "What's Updog?" This Solana-based meme coin, inspired by the classic dad joke, has a dedicated community and locked liquidity, attracting attention in the crypto space. Discussions highlight its potential for growth within the joke meta narrative.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

BUD is trending amid discussions about brand image, potential marketing strategies, and consumer sentiment following past controversies, with community members debating the effectiveness of boycotts and the company's overall direction. Some investors express concerns about the company's performance and debt, while others see it as a value opportunity, especially with upcoming events like the World Cup. Recent news includes investment in US breweries, conflicting reports about potential celebrity endorsements, and discussion of Q2 earnings.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as investors discuss its merger with Infleqtion, a quantum computing company. The community is comparing it to other quantum stocks like $IONQ and noting Infleqtion's existing contracts and revenue. Some are also weighing investment strategies between common shares and warrants as the merger date approaches.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Global X Dow 30 Covered Call ETF ($DJIA) is trending as investors assess market complacency and potential volatility amid record levels and Federal Reserve decisions on interest rates. Community discussions revolve around whether markets are overbought and the impact of potential government shutdowns. Some analysts suggest investors should prepare for consolidation, while others remain optimistic, pointing to investor sentiment and economic indicators.

Weyerhaeuser Co. engages in the manufacture, distribution, and sale of forest products. It operates through the following segments: Timberlands, Real Estate, Energy, and Natural Resources (Real Estate and ENR), and Wood Products. The Timberlands segment manages private commercial forestland worldwide and engages in growing and harvesting trees for lumber, building, pulp, paper, and other wood products. The Real Estate and ENR segment delivers premiums to timber value by identifying and monetizing higher and better use lands and capturing the full value of surface and subsurface assets. The Wood Products segment delivers lumber, structural panels, engineered wood products and complementary building products for residential, multi-family, industrial, and light commercial applications. The company was founded by Frederick T. Weyerhaeuser on January 18, 1900 and is headquartered in Seattle, WA.

Weyerhaeuser Co.

Weyerhaeuser ($WY) is trending as analysts adjust price targets and ratings, reflecting evolving perspectives on the company's outlook amid housing market uncertainties. Community members are actively discussing lumber prices, dividend prospects, and potential entry points, weighing both bullish and bearish signals. Additionally, news regarding CO2 sequestration agreements and partnerships are drawing attention to $WY's efforts in natural climate solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Bright Minds Biosciences Stock Friday?

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.
read more...

Shares of nanocap Bright Minds Biosciences, Inc. (<a class="mention" data-mention="$DRUG" data-symbol-id="DRUG" href="https://stocktwits.com/symbol/DRUG" target="_blank">$DRUG</a>) surged 47% in pre-market trading on Friday, making it one of the top five trending tickers on Stocktwits.The spike followed the company’s announcement of a non-brokered private placement of common shares priced at $21.70 per share, Thursday’s closing price, with aggregate gross proceeds expected to reach up to $35 million.Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief, conducted in partnership with the National Institutes of Health’s pain screening program.In nerve ligation pain models, BMB-201 demonstrated efficacy comparable to morphine, exhibiting superior reductions in mechanical allodynia and pain-related behaviors.The company stated that BMB-201 might provide better pain relief than traditional opioid treatments while mitigating the risks of dependency and adverse side effects.With these encouraging preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further assess its safety and efficacy in human subjects.Additionally, Firefly Neuroscience ($AIFF) had also announced a collaboration with Bright Minds to analyze data from its first-in-human Phase 1 study of its lead compound, BMB-101.Earlier this week, DRUG became an <a href="https://stocktwits.com/news-articles/markets/equity/drug-stock-falls-pre-market-after-1500-percent-surge/cJczTIWR4H">unlikely top gainer</a> across U.S. exchanges, soaring over 1,440% without any apparent catalyst. This prompted the company to issue a statement noting it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”On Stocktwits, the retail following for DRUG has surged 125% over the past week, while message volume has skyrocketed by over 290 times in the past month.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/axp-stock-falls-premarket-after-q3-earnings/cJ22K06RIm">AmEx Stock Dips Pre-Market On Q3 Revenue Miss, But Retail Focuses On Bright Spots</a>

Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.

Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief

Equity

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief


Shares of Bright Minds Biosciences, Inc. ($DRUG) dropped by as much as 34% in pre-market trading on Wednesday after an enormous 1,445% surge in the previous session.Despite the apparent profit-booking, retail interest remains high.The Vancouver-incorporated biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”That was reportedly in response to a request from the Canadian Investment Regulatory Organization, which oversees trading on the company’s home exchange.On Stocktwits, DRUG was the top trending ticker early Wednesday, with message volume spiking nearly 2,500% in the previous session. Retail interest surged, with the stock gaining 71% more followers.<stembedurl>https://stocktwits.com/TheRealShortSqueezy/message/588993273</stembedurl><stembedurl>https://stocktwits.com/etrade/message/588956007</stembedurl>Pre-market trading volume as of 7:15 a.m. ET, Wednesday, was at about 600,000 shares, far exceeding the daily average of just 24,000.Bright Minds focuses on developing drugs targeting serotonin-mediated diseases, and recently started a Phase 2 trial for a treatment aimed at drug-resistant epilepsy.The company, which has yet to generate any revenue, in August reported a net loss of $1.8 million for the nine months ending June 30, 2024 — down significantly from a $5.8 million loss during the same period in 2023.With $6.2 million in cash and working capital of $6.1 million, it said it has sufficient funds to operate through 2026.As of Tuesday’s close, Bright Minds’ stock has gained 1,991% year-to-date.The sudden rise sent its market cap soaring from $4 million to nearly $172 million before the pre-market drop.

Bright Minds focuses on developing drugs targeting serotonin-mediated diseases.

Bright Minds Biosciences Stock Falls Pre-Market After Whopping 1,445% Gain, But Retail’s Still Hooked

The biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.” 

DRUG Stock Sees Profit-Booking Pre-Market After Massive 1,445% Gain, But Retail’s Still Hooked

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences Initiates the...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Bright Minds Biosciences Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$52.22
Prev Close	$50.15
Open	$50.10
Dividend Yield	0.00%
50-Day Moving Average	$38.39
Beta	1.02
Avg. Volume	50,971.10
PE Ratio	-56.29

52-Week High	$79.02
52-Week Low	$0.94
Market Capitalization	$377.47M
EPS (Annual)	-$0.4777
Price to Book	9.94
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest DRUG News

DRUG Bright Minds Biosciences Inc